Invivyd, Inc. (IVVD)Healthcare | Biotechnology | New Haven, United States | NasdaqGM
0.61 USD
-0.03
(-4.938%) ⇩
(Oct. 14, 2026, 1 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:41 a.m. EDT
The investment case for Invivyd is currently broken by a catastrophic multi-year price trajectory and deteriorating operational fundamentals. While the company recently posted a massive 95% annual gain, this was an anomaly following three consecutive years of steep declines, leaving the stock down nearly 95% from its peak. The business is bleeding cash, with operating cash flow and free cash flow both deeply negative, and profitability remains elusive with negative margins and returns on equity. The balance sheet, while holding significant cash, is being eroded by these losses. Crucially, the market has already priced in this distress, evidenced by the overwhelming options activity where sellers and hedgers dominate the landscape. Analyst consensus is uniformly bullish, likely based on potential clinical trial success, but this ignores the severe execution risks and the fact that the stock has failed to sustain growth over the last four years. Until the company demonstrates sustained revenue growth and a path to profitability without burning through its cash reserves, the risk-reward profile remains skewed heavily toward further downside. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.275233 |
| AutoTheta | 0.280741 |
| AutoETS | 0.280789 |
| AutoARIMA | 0.281866 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 8.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.135 |
| Excess Kurtosis | -0.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.634 |
| Revenue per Share | 0.216 |
| Market Cap | 181,011,344 |
| Forward P/E | -1.12 |
| Beta | 0.95 |
| Profit Margins | -183.90% |
| Previous Name | Adagio Therapeutics, Inc. |
| Website | https://www.invivyd.com |
As of Oct. 10, 2026, 2:41 a.m. EDT: Speculators are positioning for a continued decline rather than a recovery. Put volume and open interest significantly outweigh call volume across nearly all expirations, with deep out-of-the-money puts showing massive open interest relative to calls. This indicates a heavy hedge against further downside or a bearish view that the stock will struggle to reclaim higher levels, despite some recent price stabilization.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6308571 |
| Address1 | 209 Church Street |
| All Time High | 78.82 |
| All Time Low | 0.355 |
| Ask | 0.754 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 6,059,960 |
| Average Daily Volume3 Month | 4,951,171 |
| Average Volume | 4,951,171 |
| Average Volume10Days | 6,059,960 |
| Beta | 0.947 |
| Bid | 0.4092 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.614 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6141 |
| Current Ratio | 5.869 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.64 |
| Day Low | 0.6008 |
| Debt To Equity | 4.634 |
| Display Name | Invivyd |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,778,761,800 |
| Earnings Call Timestamp Start | 1,778,761,800 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -111,888,000 |
| Ebitda Margins | -1.91704 |
| Enterprise To Ebitda | -0.346 |
| Enterprise To Revenue | 0.663 |
| Enterprise Value | 38,725,148 |
| Eps Current Year | -0.57 |
| Eps Forward | -0.55 |
| Eps Trailing Twelve Months | -0.33 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.81864 |
| Fifty Day Average Change | -0.20454001 |
| Fifty Day Average Change Percent | -0.24985343 |
| Fifty Two Week Change Percent | -63.085712 |
| Fifty Two Week High | 3.07 |
| Fifty Two Week High Change | -2.4559 |
| Fifty Two Week High Change Percent | -0.7999674 |
| Fifty Two Week Low | 0.528 |
| Fifty Two Week Low Change | 0.08609998 |
| Fifty Two Week Low Change Percent | 0.16306815 |
| Fifty Two Week Range | 0.528 - 3.07 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,628,256,600,000 |
| Float Shares | 207,831,444 |
| Forward Eps | -0.55 |
| Forward P E | -1.1165454 |
| Free Cashflow | -69,950,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 122 |
| Fullday Change | -0.03190005 |
| Fullday Change Percent | -4.938088 |
| Fullday Price | 0.6141 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.92233 |
| Gross Profits | 53,832,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07163 |
| Held Percent Institutions | 0.86935997 |
| Implied Shares Outstanding | 294,758,746 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut. |
| Long Name | Invivyd, Inc. |
| Market | us_market |
| Market Cap | 181,011,344 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_677282690 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -107,333,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 271,708,612 |
| Number Of Analyst Opinions | 3 |
| Open | 0.64 |
| Operating Cashflow | -108,422,000 |
| Operating Margins | -3.20756 |
| Overall Risk | 8 |
| Phone | 781 819 0080 |
| Prev Name | Adagio Therapeutics, Inc. |
| Previous Close | 0.646 |
| Price Eps Current Year | -1.0773684 |
| Price Hint | 4 |
| Price To Book | 1.0001628 |
| Price To Sales Trailing12 Months | 3.101368 |
| Profit Margins | -1.839 |
| Quick Ratio | 5.536 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03190005 |
| Regular Market Change Percent | -4.938088 |
| Regular Market Day High | 0.64 |
| Regular Market Day Low | 0.6008 |
| Regular Market Day Range | 0.6008 - 0.64 |
| Regular Market Open | 0.64 |
| Regular Market Previous Close | 0.646 |
| Regular Market Price | 0.6141 |
| Regular Market Time | 1,791,997,216 |
| Regular Market Volume | 1,971,668 |
| Return On Assets | -0.45668 |
| Return On Equity | -0.95889 |
| Revenue Growth | 0.212 |
| Revenue Per Share | 0.216 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 294,758,746 |
| Shares Percent Shares Out | 0.1149 |
| Shares Short | 33,858,191 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 29,787,846 |
| Short Name | Invivyd, Inc. |
| Short Percent Of Float | 0.1269 |
| Short Ratio | 4.96 |
| Source Interval | 15 |
| State | CT |
| Symbol | IVVD |
| Target High Price | 10.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 160,080,000 |
| Total Cash Per Share | 0.543 |
| Total Debt | 8,391,000 |
| Total Revenue | 58,365,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.28684 |
| Two Hundred Day Average Change | -0.67274 |
| Two Hundred Day Average Change Percent | -0.5227845 |
| Type Disp | Equity |
| Volume | 1,971,668 |
| Website | https://www.invivyd.com |
| Zip | 6,510 |